Inogen (NASDAQ:INGN) Stock Rating Upgraded by Freedom Capital

Inogen (NASDAQ:INGN) was upgraded by equities research analysts at Freedom Capital to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Inogen Price Performance

INGN opened at $6.67 on Tuesday. Inogen has a 12 month low of $5.34 and a 12 month high of $9.13. The stock has a market capitalization of $181.62 million, a price-to-earnings ratio of -7.76 and a beta of 1.70. The business has a fifty day moving average price of $6.10 and a 200 day moving average price of $6.89.

Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, February 24th. The medical technology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.10. Inogen had a negative return on equity of 11.56% and a negative net margin of 6.52%.The firm had revenue of $81.72 million during the quarter, compared to analysts’ expectations of $82.00 million. On average, research analysts anticipate that Inogen will post -1.73 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. CSM Advisors LLC acquired a new stake in shares of Inogen in the 3rd quarter valued at about $2,973,000. Armistice Capital LLC acquired a new stake in shares of Inogen in the 2nd quarter valued at about $4,668,000. GSA Capital Partners LLP acquired a new stake in shares of Inogen in the 3rd quarter valued at about $1,397,000. Royce & Associates LP boosted its position in shares of Inogen by 15.2% in the 3rd quarter. Royce & Associates LP now owns 600,968 shares of the medical technology company’s stock valued at $4,910,000 after purchasing an additional 79,238 shares during the period. Finally, Monaco Asset Management SAM boosted its position in shares of Inogen by 3.2% in the 3rd quarter. Monaco Asset Management SAM now owns 183,242 shares of the medical technology company’s stock valued at $1,497,000 after purchasing an additional 5,648 shares during the period. 89.94% of the stock is owned by institutional investors and hedge funds.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.